20 articles
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
NCI-sponsored trial evaluates safety and optimal dosing of immune checkpoint blockade following standard chemoradiation in locally advanced cervical cancer.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
